Galderma’s Announcement Regarding Nemolizumab (CHMP Positive Opinion for the Treatment of Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis)

TOKYO, December 16, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on December 13 that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended to approve nemolizumab for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis. Nemolizumab was created by Chugai, and its clinical development outside Japan is being conducted by Galderma. Please refer to the link below for details of the Galderma’s press release: CHMP recommends approval of Galderma’s nemolizumab for moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union https://www.galderma.com/news/chmp-recommends-approval-galdermas-nemolizumab-moderate-severe-atopic-dermatitis-and-prurigo Trademarks used or mentioned in this release are protected by laws.

The release as fetched from its publisher. chugai-pharm.co.jp ↗